Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium

Morris, G. M.; Coderre, Jeffrey A.; Hopewell, J. W.; Micca, Peggy L.; Rezvani, M.

doi:10.1016/0167-8140(94)90101-5

Cited by 60 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With BSH the CBE factor for tongue mucosa was much lower at ~0.3. This value is comparable with analogous CBE estimates (~0.4-0.5) for rat and dog skin (Morris et al, 1994;Gavin et al, 1997).…”

Section: Discussionsupporting

confidence: 87%

“…A CBE factor of ~2.5 has been estimated for both hamster and human skin using BPA as the boron delivery agent (Hiratsuka et al, 1991;Fukuda et al, 1994). A higher CBE estimate for BPA of ~3.7 was reported using rat skin (Morris et al, 1994). The strain, age and sex were identical to that employed in the present study.…”

Section: Discussionmentioning

confidence: 50%

“…In defining the biological effects of the 10 B(n,α) 7 Li neutron capture reaction relative to photons, the term compound biological effectiveness (CBE) factor was used as an alternative to RBE. The rational behind this has been discussed in detail previously (Morris et al, 1994). Calculation of the CBE is similar to that of the RBE factor.…”

Section: Radiation Responsementioning

confidence: 73%

“…For thermal beams, RBE values in the range 2.7-3.9 have been documented (Yamamoto, 1961;Archambeau, 1989;Morris et al, 1994). A CBE factor of ~2.5 has been estimated for both hamster and human skin using BPA as the boron delivery agent (Hiratsuka et al, 1991;Fukuda et al, 1994).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Boron microlocalization in oral mucosal tissue: implications for boron neutron capture therapy

et al. 2000

View full text Add to dashboard Cite

Summary Clinical studies of the treatment of glioma and cutaneous melanoma using boron neutron capture therapy (BNCT) are currently taking place in the USA, Europe and Japan. New BNCT clinical facilities are under construction in Finland, Sweden, England and California. The observation of transient acute effects in the oral mucosa of a number of glioma patients involved in the American clinical trials, suggests that radiation damage of the oral mucosa could be a potential complication in future BNCT clinical protocols, involving higher doses and larger irradiation field sizes. The present investigation is the first to use a high resolution surface analytical technique to relate the microdistribution of boron-10 ( 10 B) in the oral mucosa to the biological effectiveness of the 10 B(n,α) 7 Li neutron capture reaction in this tissue. The two boron delivery agents used clinically in Europe/Japan and the USA, borocaptate sodium (BSH) and p-boronophenylalanine (BPA), respectively, were evaluated using a rat ventral tongue model. 10 B concentrations in various regions of the tongue mucosa were estimated using ion microscopy. In the epithelium, levels of 10 B were appreciably lower after the administration of BSH than was the case after BPA. The epithelium:blood 10 B partition ratios were 0.2:1 and 1:1 for BSH and BPA respectively. The 10 B content of the lamina propria was higher than that measured in the epithelium for both BSH and BPA. The difference was most marked for BSH, where 10 B levels were a factor of six higher in the lamina propria than in the epithelium. The concentration of 10 B was also measured in blood vessel walls where relatively low levels of accumulation of BSH, as compared with BPA, was demonstrated in blood vessel endothelial cells and muscle. Vessel wall:blood 10 B partition ratios were 0.3:1 and 0.9:1 for BSH and BPA respectively. Evaluation of tongue mucosal response (ulceration) to BNC irradiation indicated a considerably reduced radiation sensitivity using BSH as the boron delivery agent relative to BPA. The compound biological effectiveness (CBE) factor for BSH was estimated at 0.29 ± 0.02. This compares with a previously published CBE factor for BPA of 4.87 ± 0.16. It was concluded that variations in the microdistribution profile of 10 B, using the two boron delivery agents, had a significant effect on the response of oral mucosa to BNC irradiation. From a clinical perspective, based on the findings of the present study, it is probable that potential radiationinduced oral mucositis will be restricted to BNCT protocols involving BPA. However, a thorough high resolution analysis of 10 B microdistribution in human oral mucosal tissue, using a technique such as ion microscopy, is a prerequisite for the use of experimentally derived CBE factors in clinical BNCT.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 50%

Section: Radiation Responsementioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Boron microlocalization in oral mucosal tissue: implications for boron neutron capture therapy

et al. 2000

View full text Add to dashboard Cite

show abstract

“…In the radiobiology of BNCT, the term "Compound Biological Effectiveness" (CBE) 22,23 of the 10 B dose component is used to distinguish the ratio of doses experimentally obtained when looking at a given level of effect relative to photons, from the traditional Relative Biological Effectiveness (RBE) factor, which should only depend on radiation quality. This departure from a "pure" RBE factor can be explained considering that, for a non-uniform boron microdistribution (and in consequence, a non-uniform production of boron reactions), the calculated KERMA differs from the actual average dose deposited on cells, thereby under or overestimating the "true" value.…”

Section: The Microdosimetry Of the Boron Neutron Capture Reactionmentioning

confidence: 99%